In8Bio (INAB) Assets Average (2021 - 2026)
In8Bio (INAB) posted Assets Average of $29.3 million for Q1 2026, up 19.36% sequentially from $24.5 million in Q4 2025, and up 43.45% YoY from $20.4 million in Q1 2025.
In8Bio (INAB) Assets Average (2021 - 2026) Analysis & Trends
In8Bio has reported Assets Average for 6 years, with the latest figure at $29.3 million in Q1 2026.
- Quarterly Assets Average rose 43.45% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.3 million (up 43.45% YoY) and the FY2025 annual result came in at $26.6 million, down 2.61% from the prior year.
- Assets Average advanced to $29.3 million in Q1 2026 per INAB's latest filing, from $24.5 million in the prior quarter.
- Over five years, Assets Average peaked at $39.4 million in Q1 2022 and troughed at $18.1 million in Q3 2025.
- A 5-year average of $27.1 million and a median of $28.0 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2026: Assets Average plunged 38.4% in 2024, then surged 43.45% in 2026.
- Over 5 years, Assets Average stood at $35.7 million in 2022, then dropped by 16.11% to $30.0 million in 2023, then sank by 38.4% to $18.5 million in 2024, then jumped by 32.89% to $24.5 million in 2025, then climbed by 19.36% to $29.3 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $29.3 million, $24.5 million, and $18.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 19.82 Bn |
| 10 | In8Bio | 23.11 Mn | 23.11 Mn | - | 24.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.01 Mn |
| Mar 31, 2026 | 29.27 Mn |
| Dec 31, 2025 | 24.53 Mn |
| Sep 30, 2025 | 18.07 Mn |
| Jun 30, 2025 | 19.62 Mn |
| Mar 31, 2025 | 20.41 Mn |
| Dec 31, 2024 | 18.46 Mn |
| Sep 30, 2024 | 19.23 Mn |
| Dec 31, 2023 | 29.96 Mn |
| Sep 30, 2023 | 27.96 Mn |
| Jun 30, 2023 | 27.20 Mn |
| Mar 31, 2023 | 28.86 Mn |
| Dec 31, 2022 | 35.71 Mn |
| Sep 30, 2022 | 34.69 Mn |
| Jun 30, 2022 | 33.76 Mn |
| Mar 31, 2022 | 39.38 Mn |
| Dec 31, 2021 | 44.68 Mn |
| Sep 30, 2021 | 32.35 Mn |